Certara, Inc. (CERT) — SEC Form D Filing
Certara, Inc. (CERT) filed an SEC Form D on April 28, 2026, reporting $8.62M raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- April 28, 2026
- Amount reported
- $8.62M
- Round stage
- Series A
- Industry
- Pharmaceuticals
- Website
- https://www.certara.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Current drug development processes are not meeting the demands for speed, innovation, and efficiency necessary for developing new drugs.
Solution
Certara provides predictive simulation, data-driven modeling, and AI solutions to enhance drug discovery, optimize clinical data, and accelerate drug development across all phases, from discovery to market access.
Why now
There is an urgent need for faster, more innovative drug development solutions to meet the rising demands of the healthcare sector.
Verdict
Investors said yes at that moment because the narrative addressed a pressing need for efficiency in drug development, not because similar companies had cleared the market before. They were betting on the potential of advanced technology like predictive simulations and AI to transform an outdated system. The limited upside lies in the crowded nature of the pharmaceutical technology space, where numerous players are already established, reducing the durability of any competitive advantage.
Source: SEC EDGAR Form D filing